Phaseline

Companies › Lipocine

Lipocine: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Neurology, Psychiatry; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Brexanolone
GABA-A receptor; anion channel positive allosteric modulator
GABRA1, GABRB2, GABRG2, GABRB3, GABRA4Phase 3Depression, Postpartum; Alzheimer Dementia; PTSDAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05223829BrexanolonePhase 1PTSDPsychiatryDec 2025
NCT04838301BrexanolonePhase 2Alzheimer DementiaNeurologyNov 2026
NCT07822321BrexanolonePhase 3Depression, PostpartumPsychiatryAug 2027

From the company's SEC filings

Cash and short-term investments of $21m on 2026-09-30; operating cash outflow about $10m a year; runway about 27 months at that burn, to Dec 2028; 2 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

GABRA1 (1) GABRB2 (1) GABRG2 (1) GABRB3 (1) GABRA4 (1)

Companies with the same targets

Ono Pharmaceutical UCB Biopharma SRL Haisco Pharmaceutical Group SK Life Science Acacia Pharma Sedana Medical Seaport Therapeutics Neurodawn Pharmaceutical Umecrine Cognition

Companies built like this

Xenon Pharmaceuticals Rapport Therapeutics Sichuan Jishengtang Pharmaceutical LB Pharmaceuticals Impax Laboratories

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.